National Heart, Lung, and Blood Institute; Submission for OMB Review; Comment Request, National Donor Research and Education Study-II
Federal RegisterDec 29, 1997
Ask Donna
What actually matters in this document.
Text
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Submission for OMB
Review; Comment Request, National Donor Research and Education Study-II
SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995, for opportunity for public comment
on proposed data collection projects, the National Heart, Lung, and
Blood Institute (NHLBI), the National Institutes of Health (NIH), will
publish periodic summaries of proposed projects to be submitted to the
Office of Management and Budget (OMB) for review and approval. This
proposed information collection was previously published in Volume 62,
Number 86 of the Federal Register on May 5, 1997 (page 24,492) and
allowed 60 days for public comment. One comment was received. An
individual requested a summary of the study protocol, which was
provided to them. The National Institutes of Health may not conduct or
sponsor, and the respondent is not required to respond to, an
information collection that has been extended, revised or implemented
on or after October 1, 1995 unless it displays a currently valid OMB
control number.
Proposed Collection
Title: National Donor Research and Education Study-II. Type of
Information Collection Request: Reinstatement with changes to OMB
#0925-0383, Expiration date: 1/31/96. Need and Use of Information
Collection: This study is the second large anonymous mail survey to be
sent to a random sample of blood donors at five blood centers
participating in the Retrovirus Epidemiology Donor Study (REDS). In
addition to the REDS blood centers, this survey will also be sent to a
sample of donors in selected non-REDS regions that utilize a variety of
donor incentives. Study results will provide data for monitoring the
safety of the U.S. blood supply, and will facilitate the development,
evaluation and refinement of educational, recruitment and qualification
strategies for U.S. blood donors. The proposed new study will update
and extend the unique findings obtained in the first blood donor survey
so as to minimize the likelihood that donors with risk factors for
transfusion-transmitted diseases will enter the blood donor pool. There
is a strong likelihood that, like the first survey effort, the
resulting findings will be directly applied to blood banking
operational practice. The new survey is specifically designed to obtain
data on the prevalence and impact of donor incentives on donor
retention and blood safety. The FDA has identified this as a priority
area for investigation. Other specific objectives of this survey are
to: (1) Evaluate donor understanding and acceptance, and the safety
impact of newly-changed laboratory and donor screening procedures that
have been implemented since the previous donor survey study (e.g.,
removal of the confidential unit exclusion ``CUE'' process at two REDS
sites; additional questions about Creutzfeldt-jakob and parasitic
diseases; and addition of HIV p24 antigen testing); (2) Estimate the
efficacy, safety impact and donor acceptance of new donor screening
procedures that are anticipated to occur within the next 12-24 months
(e.g., improved CUE procedures, implementation of computer-assisted
donor screening); (3) Provide ``pre-'' (baseline) and ``post-''
(evaluation) measures for new donor qualification procedures expected
to occur operationally at blood centers within the time period of study
including: deferral for intranasal cocaine use in the past year;
modification of the time period for sexual risk deferrals from ``since
1977'' to within the past (12 or 24) months; clarification of wording
regarding sexual contact with ``at-risk'' individuals; and addition of
questions about donating primarily for the purpose of receiving the
test results for the AIDS virus; (4) Assess changes in the prevalence
and characteristics of donors who report donating for therapeutic
reasons (e.g., those with iron storage disease), and donors who report
donating primarily to receive test results for the AIDS virus as a
result of the March 1996 implementation of HIV p24 antigen testing; (5)
Determine the extent to which active donors with reactive tests for
anti-HBc and syphilis have increased levels of behavioral risks that
should have resulted in deferral; (6) Measure the extent to which
seropositivity for current syphilis screening tests predicts a recent
history of diagnosed syphilis; (7) Measure blood donor knowledge of
infectious disease risks and the behavioral factors that should defer
them from donating, to identify weaknesses in the current donor
educational process, and (8) Assess the attitudes of donors regarding
establishment of stored frozen repositories from their donations, use
of these samples for future research testing designed to improve
transfusion safety, and the adequacy of different levels of
[[Page 67644]]
informed consent. Frequency of Response: One-time data collection.
Affected Public: Individuals.
----------------------------------------------------------------------------------------------------------------
Estimated
Estimated Average total
Estimated number of burden annual
Type of respondents number of responses hours per burden
respondents per responses hours
respondent requested
----------------------------------------------------------------------------------------------------------------
Blood Donors................................................ 78,000 1 .3333 25,997
----------------------------------------------------------------------------------------------------------------
The annualized cost to respondents is estimated at: $259,974 (based
on $10 per hour). There are no Capital Costs to report. There are no
Operating or Maintenance Costs to report.
Request For Comments
Written comments and/or suggestions from the public and affected
agencies are invited on one or more of the following points: (1)
Whether the proposed collection of information is necessary for the
proper performance of the function of the agency, including whether the
information will have practical utility; (2) The accuracy of the
agency's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
used; (3) Ways to enhance the quality, utility, and clarity of the
information to be collected; and (4) Ways to minimize the burden of the
collection of information on those who are to respond, including the
use of appropriate automated, electronic, mechanical or other
technological collection techniques or other forms of information
technology.
Direct Comments To OMB
Written comments and/or suggestions regarding the item(s) contained
in this notice, especially regarding the estimated public burden and
associated response time, should be directed to the: Office of
Management and Budget, Office of Regulatory Affairs, New Executive
Office Building, Room 10235, Washington, DC 20503, Attention: Desk
Officer for NIH. To request more information on the proposed project or
obtain a copy of the data collection plans and instruments contact: Dr.
George J. Nemo, Group Leader, Transfusion Medicine, Scientific Research
Group, Division of Blood Diseases and Resources, NHLBI, NIH, Two
Rockledge Centre, Suite 10042, 6701 Rockledge Drive, MSC 7950,
Bethesda, MD 20892-7950, or call non-toll free number (301) 435-0075 or
e-mail your request, including your address to:
[email protected].
Comments Due Date
Comments regarding this information collection are best assured of
having their full effect if received on or before January 28, 1998.
Dated: December 17, 1997.
Sheila E. Merritt,
Executive Officer, NHLBI.
[FR Doc. 97-33745 Filed 12-24-97; 8:45 am]
BILLING CODE 4140-01-M
This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.